CA Patent

CA2957588C — Tasimelteon for treating smith-magenis syndrome

Assigned to Vanda Pharmaceuticals Inc · Expires 2021-08-31 · 5y expired

What this patent protects

The invention relates to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS) using Tasimelteon.

USPTO Abstract

The invention relates to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS) using Tasimelteon.

Drugs covered by this patent

Patent Metadata

Patent number: CA2957588C
Jurisdiction: CA
Classification: —
Expires: 2021-08-31
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.